Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Celanese Corporation Reports Second Quarter Earnings

Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported second quarter 2024 U.S. GAAP diluted earnings per share of $1.42 and adjusted earnings per share of $2.38. The Company generated net sales of $2.7 billion in the quarter, an increase of 2 percent from the prior quarter, reflecting a sequential increase in volume of 4 percent and sequential decrease in pricing of 2 percent.

Celanese continued to focus on execution of its controllable action plan, including driving volume growth through the project pipeline model, lowering costs through reduction of capacity in high-cost locations, and improving business efficiency through the integration of the acquired Mobility & Materials (M&M) businesses into a single SAP ERP system. These actions were especially impactful during a quarter that presented significant external headwinds. Among these headwinds were a series of outages and curtailments from multiple suppliers that led to the Company's declaration of force majeure for acetic acid and VAM sold in the Western Hemisphere, as well as persistent poor demand conditions across many of the Company's end-markets. Against the backdrop of these headwinds, the results reflect meaningful realization of business improvements from the execution of the Company's action plans. Celanese reported second quarter operating profit of $250 million, adjusted EBIT of $451 million, and operating EBITDA of $632 million at margins of 9, 17, and 24 percent, respectively.

The difference between U.S. GAAP diluted earnings per share and adjusted earnings per share in the second quarter was primarily due to Certain Items totaling $102 million.1

"In the second quarter, we delivered a double-digit sequential expansion of adjusted EBIT in spite of some of the most severe external challenges we've faced in many years," said Lori Ryerkerk, chair and chief executive officer. "The prolonged weak demand environment we have continued to experience over the past several quarters was compounded by multiple supplier failures that led us to declare force majeure for acetic acid and VAM sold in the Western Hemisphere. In this environment, we stayed focused on delivering on our action plan, which resulted in the highest ever contribution from the Engineered Materials business in our history. This highlights the importance of our execution focus, and I thank our teams for their resilience and agility to achieve these results."

_______________________________________

1 Mainly driven by shutdown-related costs and M&A-related costs

Second Quarter 2024 Financial Highlights:

 

Three Months Ended

 

June 30,

2024

 

March 31,

2024

 

June 30,

2023

 

(unaudited)

 

(In $ millions, except per share data)

Net Sales

 

 

 

 

 

Engineered Materials

 

1,467

 

 

 

1,378

 

 

 

1,585

 

Acetyl Chain

 

1,202

 

 

 

1,261

 

 

 

1,233

 

Intersegment Eliminations

 

(18

)

 

 

(28

)

 

 

(23

)

Total

 

2,651

 

 

 

2,611

 

 

 

2,795

 

 

 

 

 

 

 

Operating Profit (Loss)

 

 

 

 

 

Engineered Materials

 

138

 

 

 

89

 

 

 

158

 

Acetyl Chain

 

242

 

 

 

254

 

 

 

295

 

Other Activities

 

(130

)

 

 

(133

)

 

 

(118

)

Total

 

250

 

 

 

210

 

 

 

335

 

 

 

 

 

 

 

Net Earnings (Loss)

 

153

 

 

 

124

 

 

 

221

 

 

 

 

 

 

 

Adjusted EBIT(1)

 

 

 

 

 

Engineered Materials

 

265

 

 

 

201

 

 

 

205

 

Acetyl Chain

 

277

 

 

 

296

 

 

 

332

 

Other Activities

 

(91

)

 

 

(90

)

 

 

(93

)

Total

 

451

 

 

 

407

 

 

 

444

 

 

 

 

 

 

 

Equity Earnings and Dividend Income, Other Income (Expense)

 

 

 

 

 

Engineered Materials

 

49

 

 

 

50

 

 

 

20

 

Acetyl Chain

 

33

 

 

 

36

 

 

 

32

 

 

 

 

 

 

 

Operating EBITDA(1)

 

632

 

 

 

583

 

 

 

616

 

Diluted EPS - continuing operations

$

1.42

 

 

$

1.10

 

 

$

2.00

 

Diluted EPS - total

$

1.41

 

 

$

1.10

 

 

$

2.01

 

Adjusted EPS(1)

$

2.38

 

 

$

2.08

 

 

$

2.17

 

 

 

 

 

 

 

Net cash provided by (used in) investing activities

 

(91

)

 

 

(151

)

 

 

(163

)

Net cash provided by (used in) financing activities

 

(489

)

 

 

(259

)

 

 

(447

)

Net cash provided by (used in) operating activities

 

292

 

 

 

101

 

 

 

762

 

Free cash flow(1)

 

173

 

 

 

(40

)

 

 

611

 

____________________________

(1) See "Non-US GAAP Financial Measures" below.

Second Quarter Business Segment Overview

Acetyl Chain

The Acetyl Chain delivered second quarter net sales of $1.2 billion, a 5 percent decrease from the prior quarter. Volume decreased by 1 percent sequentially due to the effects of the force majeure, delayed timing of opportunistic spot sales, and muted seasonal improvements. Second quarter pricing across the Acetyl Chain decreased by 4 percent sequentially. The multiple supplier outages and curtailments had a significant impact on the ability of Celanese to produce at the Clear Lake site, the Company's lowest cost and lowest carbon footprint acetic acid unit. The second quarter total losses of Clear Lake acetic acid attributable to unplanned supplier disruptions was the highest in over 15 years. In the face of these headwinds, the Acetyl Chain worked to assure virtually all customer needs were met. The business delivered second quarter operating profit of $242 million, adjusted EBIT of $277 million, and operating EBITDA of $338 million at margins of 20, 23, and 28 percent, respectively. The Acetyl Chain has continued to exercise the unique optionality of the business model in the face of chronic low demand. The flexibility of the model allowed the business to expand volumes in downstream markets in Asia, despite poor demand conditions, by pivoting to alternate applications with available demand. The Acetyl Chain will continue to leverage this optionality to optimize outcomes through the extended demand trough.

Engineered Materials

Engineered Materials reported second quarter net sales of $1.5 billion, representing a sequential increase of 6 percent. Sequential growth was driven by a 7 percent increase in volume and stable pricing, partially offset by a small currency impact. The breadth of volume growth was widespread across the portfolio, with all 10 of the largest polymer families achieving sequential growth. This was further bolstered by a favorable mix, primarily in higher margin products and applications like Vamac® and medical implants, contributing to the overall volume increase and demonstrating the effectiveness of the project pipeline model. Engineered Materials delivered second quarter operating profit of $138 million, record adjusted EBIT of $265 million, and record operating EBITDA of $375 million. These figures represent margins of 9, 18, and 26 percent, respectively with sequential earnings improvements of 55, 32, and 24 percent. In addition to the volume growth, the sequential improvement in earnings was driven by incremental synergies and the realization of lower raw material costs. Synergy capture in the quarter included initial earnings contributions from previous initiatives such as the closure of nylon 6,6 polymerization in Uentrop, Germany. For the second consecutive quarter, these strategic actions have lifted the performance of the former M&M product portfolio to deliver the highest quarterly contribution since the acquisition.

Cash Flow and Tax

Celanese reported second quarter operating cash flow of $292 million and free cash flow of $173 million, which included cash capital expenditures of $105 million. Celanese returned $77 million in cash to shareholders via dividends in the quarter. The Company repaid a bond of approximately $500 million that matured in the second quarter as part of its deleveraging plan.

The effective U.S. GAAP income tax rate was an expense of 16 percent for the second quarter compared to a benefit of 2 percent for the same quarter in 2023. The effective income tax rate for the current year was higher compared to the same period in 2023, primarily due to current year tax effects related to internal debt restructuring transactions, prior year non-recurring decreases in valuation allowances on U.S. foreign tax credit carryforwards due to changes in forecasted foreign sourced income and expenses during the carryforward period, and increased earnings in high-taxed jurisdictions related to improved economic conditions in the current year. The effective tax rate for adjusted earnings was 9 percent based on expected jurisdictional earnings mix for the full year and consideration of other non-recurring U.S. GAAP items.

Outlook

"We are encouraged to see the tangible realization of our value creation initiatives in our second quarter results, and we are confident that those benefits will continue through the year," said Lori Ryerkerk. "Given the continued lack of evidence of meaningful demand recovery and the increasing pricing pressure from this low demand environment, our focus will remain on what we can control to deliver a sustainable earnings lift for Celanese. We expect the third quarter will bring an easing of the effects of the force majeure, and further improvements to our business driven by our action plans. Because of our foundational value creation initiatives, I am confident we will continue to deliver improved earnings performance in the third quarter and through the remainder of the year."

The Company anticipates third quarter adjusted earnings per share of $2.75 to $3.00. Furthermore, based on the effects of the second quarter force majeure and persistent demand challenges, the Company anticipates full year adjusted earnings per share of $10.25 to $10.75.

Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.

The Company's prepared remarks related to the second quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on August 1, 2024. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.

Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

Forward-Looking Statements

This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine and fuel oil and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to timely or effectively continue to integrate the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition") in order to realize the anticipated benefits of the M&M Acquisition, including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; risks and costs associated with increased leverage from the M&M Acquisition, including increased interest expense and potential reduction of business and strategic flexibility; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, terrorism or political unrest, public health crises (including, but not limited to, the COVID-19 pandemic), or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia-Ukraine conflict or the Israel-Hamas conflict) or terrorist incidents or as a result of weather, natural disasters, or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate; changes in currency exchange rates and interest rates; our level of indebtedness, which could diminish our ability to raise additional capital to fund operations or limit our ability to react to changes in the economy or the chemicals industry; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Non-GAAP Financial Measures

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-US GAAP Financial Information

This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for operating EBITDA margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.

Definitions of Non-US GAAP Financial Measures

  • Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.
  • Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales.
  • Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.



    Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
  • Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our noncontrolling interest joint ventures. We do not provide reconciliations for free cash flow on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.

Reconciliation of Non-US GAAP Financial Measures

Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about August 1, 2024 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

Supplemental Information

Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.

Consolidated Statements of Operations - Unaudited

 

 

Three Months Ended

 

June 30,

2024

 

March 31,

2024

 

June 30,

2023

 

(In $ millions, except share and per share data)

Net sales

2,651

 

 

2,611

 

 

2,795

 

Cost of sales

(2,010

)

 

(2,057

)

 

(2,109

)

Gross profit

641

 

 

554

 

 

686

 

Selling, general and administrative expenses

(255

)

 

(265

)

 

(274

)

Amortization of intangible assets

(38

)

 

(41

)

 

(42

)

Research and development expenses

(33

)

 

(34

)

 

(40

)

Other (charges) gains, net

(48

)

 

(14

)

 

(10

)

Foreign exchange gain (loss), net

(9

)

 

11

 

 

15

 

Gain (loss) on disposition of businesses and assets, net

(8

)

 

(1

)

 

 

Operating profit (loss)

250

 

 

210

 

 

335

 

Equity in net earnings (loss) of affiliates

51

 

 

55

 

 

23

 

Non-operating pension and other postretirement employee benefit (expense) income

2

 

 

2

 

 

(2

)

Interest expense

(174

)

 

(169

)

 

(182

)

Interest income

10

 

 

13

 

 

7

 

Dividend income - equity investments

31

 

 

34

 

 

31

 

Other income (expense), net

13

 

 

12

 

 

4

 

Earnings (loss) from continuing operations before tax

183

 

 

157

 

 

216

 

Income tax (provision) benefit

(29

)

 

(33

)

 

4

 

Earnings (loss) from continuing operations

154

 

 

124

 

 

220

 

Earnings (loss) from operation of discontinued operations

(1

)

 

 

 

 

Income tax (provision) benefit from discontinued operations

 

 

 

 

1

 

Earnings (loss) from discontinued operations

(1

)

 

 

 

1

 

Net earnings (loss)

153

 

 

124

 

 

221

 

Net (earnings) loss attributable to noncontrolling interests

2

 

 

(3

)

 

(1

)

Net earnings (loss) attributable to Celanese Corporation

155

 

 

121

 

 

220

 

Amounts attributable to Celanese Corporation

 

 

 

 

 

Earnings (loss) from continuing operations

156

 

 

121

 

 

219

 

Earnings (loss) from discontinued operations

(1

)

 

 

 

1

 

Net earnings (loss)

155

 

 

121

 

 

220

 

Earnings (loss) per common share - basic

 

 

 

 

 

Continuing operations

1.43

 

 

1.11

 

 

2.01

 

Discontinued operations

(0.01

)

 

 

 

0.01

 

Net earnings (loss) - basic

1.42

 

 

1.11

 

 

2.02

 

Earnings (loss) per common share - diluted

 

 

 

 

 

Continuing operations

1.42

 

 

1.10

 

 

2.00

 

Discontinued operations

(0.01

)

 

 

 

0.01

 

Net earnings (loss) - diluted

1.41

 

 

1.10

 

 

2.01

 

Weighted average shares (in millions)

 

 

 

 

 

Basic

109.3

 

 

109.1

 

 

108.9

 

Diluted

109.5

 

 

109.5

 

 

109.3

 

Consolidated Balance Sheets - Unaudited

 

As of

June 30,

2024

 

As of

December 31,

2023

 

 

(In $ millions)

ASSETS

 

 

 

Current Assets

 

 

 

Cash and cash equivalents

1,185

 

 

1,805

 

Trade receivables - third party and affiliates, net

1,264

 

 

1,243

 

Non-trade receivables, net

662

 

 

541

 

Inventories

2,464

 

 

2,357

 

Other assets

329

 

 

272

 

Total current assets

5,904

 

 

6,218

 

Investments in affiliates

1,215

 

 

1,220

 

Property, plant and equipment, net

5,382

 

 

5,584

 

Operating lease right-of-use assets

381

 

 

422

 

Deferred income taxes

1,608

 

 

1,677

 

Other assets

579

 

 

524

 

Goodwill

6,899

 

 

6,977

 

Intangible assets, net

3,844

 

 

3,975

 

Total assets

25,812

 

 

26,597

 

LIABILITIES AND EQUITY

 

 

 

Current Liabilities

 

 

 

Short-term borrowings and current installments of long-term debt - third party and affiliates

1,977

 

 

1,383

 

Trade payables - third party and affiliates

1,538

 

 

1,510

 

Other liabilities

1,106

 

 

1,154

 

Income taxes payable

5

 

 

25

 

Total current liabilities

4,626

 

 

4,072

 

Long-term debt, net of unamortized deferred financing costs

11,058

 

 

12,301

 

Deferred income taxes

1,039

 

 

999

 

Uncertain tax positions

292

 

 

300

 

Benefit obligations

435

 

 

457

 

Operating lease liabilities

282

 

 

325

 

Other liabilities

471

 

 

591

 

Commitments and Contingencies

 

 

 

Shareholders' Equity

 

 

 

Treasury stock, at cost

(5,487

)

 

(5,488

)

Additional paid-in capital

394

 

 

394

 

Retained earnings

13,051

 

 

12,929

 

Accumulated other comprehensive income (loss), net

(792

)

 

(744

)

Total Celanese Corporation shareholders' equity

7,166

 

 

7,091

 

Noncontrolling interests

443

 

 

461

 

Total equity

7,609

 

 

7,552

 

Total liabilities and equity

25,812

 

 

26,597

 

Non-US GAAP Financial Measures and Supplemental Information

August 1, 2024

In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.

Purpose

The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-US GAAP financial measures. This document is updated quarterly.

Presentation

This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.

Use of Non-US GAAP Financial Measures

From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with US GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable US GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.

Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other US GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.

Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.

This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.

Specific Measures Used

This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity.

Definitions

  • Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as Adjusted EBIT.
  • Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that Operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. Operating EBITDA margin is defined by the Company as Operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as Operating EBITDA.
  • Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as Operating profit (loss) attributable to Celanese Corporation.
  • Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.



    Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
  • Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures. We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure. We do not provide reconciliations for free cash flow on a forward-looking basis when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
  • Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
  • Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our shareholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.

Supplemental Information

Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:

  • Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
  • Cash dividends received from our equity investments.
  • For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as NCI. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.

Results Unaudited

The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

 

Table 1

Celanese Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions)

Net earnings (loss) attributable to Celanese Corporation

155

 

 

121

 

 

1,960

 

 

698

 

 

951

 

 

220

 

 

91

 

(Earnings) loss from discontinued operations

1

 

 

 

 

9

 

 

6

 

 

1

 

 

(1

)

 

3

 

Interest income

(10

)

 

(13

)

 

(39

)

 

(12

)

 

(12

)

 

(7

)

 

(8

)

Interest expense

174

 

 

169

 

 

720

 

 

178

 

 

178

 

 

182

 

 

182

 

Refinancing expense

 

 

 

 

7

 

 

 

 

7

 

 

 

 

 

Income tax provision (benefit)

29

 

 

33

 

 

(790

)

 

(575

)

 

(236

)

 

(4

)

 

25

 

Certain Items attributable to Celanese Corporation (Table 8)

102

 

 

97

 

 

(114

)

 

139

 

 

(438

)

 

54

 

 

131

 

Adjusted EBIT

451

 

 

407

 

 

1,753

 

 

434

 

 

451

 

 

444

 

 

424

 

Depreciation and amortization expense(1)

181

 

 

176

 

 

691

 

 

174

 

 

173

 

 

172

 

 

172

 

Operating EBITDA

632

 

 

583

 

 

2,444

 

 

608

 

 

624

 

 

616

 

 

596

 

 
 

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions)

Engineered Materials

11

 

 

45

 

 

15

 

 

15

 

 

 

 

 

 

 

Acetyl Chain

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Activities(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

Accelerated depreciation and amortization expense

11

 

 

45

 

 

15

 

 

15

 

 

 

 

 

 

 

Depreciation and amortization expense(1)

181

 

 

176

 

 

691

 

 

174

 

 

173

 

 

172

 

 

172

 

Total depreciation and amortization expense

192

 

 

221

 

 

706

 

 

189

 

 

173

 

 

172

 

 

172

 

_____________________

(1)

Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.

(2)

Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

 
Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions, except percentages)

Operating Profit (Loss) / Operating Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

138

 

 

9.4

%

 

89

 

 

6.5

%

 

1,083

 

 

17.6

%

 

122

 

 

8.7

%

 

691

 

 

45.2

%

 

158

 

 

10.0

%

 

112

 

 

6.9

%

Acetyl Chain

242

 

 

20.1

%

 

254

 

 

20.1

%

 

1,109

 

 

22.7

%

 

264

 

 

22.4

%

 

272

 

 

22.3

%

 

295

 

 

23.9

%

 

278

 

 

22.2

%

Other Activities(1)

(130

)

 

 

 

(133

)

 

 

 

(505

)

 

 

 

(127

)

 

 

 

(121

)

 

 

 

(118

)

 

 

 

(139

)

 

 

Total

250

 

 

9.4

%

 

210

 

 

8.0

%

 

1,687

 

 

15.4

%

 

259

 

 

10.1

%

 

842

 

 

30.9

%

 

335

 

 

12.0

%

 

251

 

 

8.8

%

Less: Net Earnings (Loss) Attributable to NCI for Engineered Materials

(4

)

 

 

 

(1

)

 

 

 

(3

)

 

 

 

1

 

 

 

 

(2

)

 

 

 

(2

)

 

 

 

 

 

 

Less: Net Earnings (Loss) Attributable to NCI for Acetyl Chain

2

 

 

 

 

4

 

 

 

 

7

 

 

 

 

2

 

 

 

 

 

 

 

 

3

 

 

 

 

2

 

 

 

Operating Profit (Loss) Attributable to Celanese Corporation

252

 

 

9.5

%

 

207

 

 

7.9

%

 

1,683

 

 

15.4

%

 

256

 

 

10.0

%

 

844

 

 

31.0

%

 

334

 

 

11.9

%

 

249

 

 

8.7

%

Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

142

 

 

9.7

%

 

90

 

 

6.5

%

 

1,086

 

 

17.7

%

 

121

 

 

8.6

%

 

693

 

 

45.4

%

 

160

 

 

10.1

%

 

112

 

 

6.9

%

Acetyl Chain

240

 

 

20.0

%

 

250

 

 

19.8

%

 

1,102

 

 

22.6

%

 

262

 

 

22.2

%

 

272

 

 

22.3

%

 

292

 

 

23.7

%

 

276

 

 

22.1

%

Other Activities(1)

(130

)

 

 

 

(133

)

 

 

 

(505

)

 

 

 

(127

)

 

 

 

(121

)

 

 

 

(118

)

 

 

 

(139

)

 

 

Total

252

 

 

9.5

%

 

207

 

 

7.9

%

 

1,683

 

 

15.4

%

 

256

 

 

10.0

%

 

844

 

 

31.0

%

 

334

 

 

11.9

%

 

249

 

 

8.7

%

Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

49

 

 

 

 

50

 

 

 

 

87

 

 

 

 

45

 

 

 

 

12

 

 

 

 

20

 

 

 

 

10

 

 

 

Acetyl Chain

33

 

 

 

 

36

 

 

 

 

132

 

 

 

 

33

 

 

 

 

33

 

 

 

 

32

 

 

 

 

34

 

 

 

Other Activities(1)

13

 

 

 

 

15

 

 

 

 

34

 

 

 

 

28

 

 

 

 

1

 

 

 

 

6

 

 

 

 

(1

)

 

 

Total

95

 

 

 

 

101

 

 

 

 

253

 

 

 

 

106

 

 

 

 

46

 

 

 

 

58

 

 

 

 

43

 

 

 

Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

 

 

 

 

 

 

 

 

(1

)

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acetyl Chain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Activities(1)

2

 

 

 

 

2

 

 

 

 

(68

)

 

 

 

(66

)

 

 

 

(1

)

 

 

 

(2

)

 

 

 

1

 

 

 

Total

2

 

 

 

 

2

 

 

 

 

(69

)

 

 

 

(67

)

 

 

 

(1

)

 

 

 

(2

)

 

 

 

1

 

 

 

Certain Items Attributable to Celanese Corporation (Table 8)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

74

 

 

 

 

61

 

 

 

 

(324

)

 

 

 

34

 

 

 

 

(476

)

 

 

 

25

 

 

 

 

93

 

 

 

Acetyl Chain

4

 

 

 

 

10

 

 

 

 

24

 

 

 

 

5

 

 

 

 

5

 

 

 

 

8

 

 

 

 

6

 

 

 

Other Activities(1)

24

 

 

 

 

26

 

 

 

 

186

 

 

 

 

100

 

 

 

 

33

 

 

 

 

21

 

 

 

 

32

 

 

 

Total

102

 

 

 

 

97

 

 

 

 

(114

)

 

 

 

139

 

 

 

 

(438

)

 

 

 

54

 

 

 

 

131

 

 

 

Adjusted EBIT / Adjusted EBIT Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

265

 

 

18.1

%

 

201

 

 

14.6

%

 

848

 

 

13.8

%

 

199

 

 

14.2

%

 

229

 

 

15.0

%

 

205

 

 

12.9

%

 

215

 

 

13.2

%

Acetyl Chain

277

 

 

23.0

%

 

296

 

 

23.5

%

 

1,258

 

 

25.8

%

 

300

 

 

25.4

%

 

310

 

 

25.4

%

 

332

 

 

26.9

%

 

316

 

 

25.3

%

Other Activities(1)

(91

)

 

 

 

(90

)

 

 

 

(353

)

 

 

 

(65

)

 

 

 

(88

)

 

 

 

(93

)

 

 

 

(107

)

 

 

Total

451

 

 

17.0

%

 

407

 

 

15.6

%

 

1,753

 

 

16.0

%

 

434

 

 

16.9

%

 

451

 

 

16.6

%

 

444

 

 

15.9

%

 

424

 

 

14.9

%

____________________________

(1)

Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

 

Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)

Q2 '24

 

Q1 '24

 

2023

 

 

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions, except percentages)

Depreciation and Amortization Expense(1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

110

 

 

 

 

102

 

 

 

 

447

 

 

 

 

112

 

 

 

 

111

 

 

 

 

112

 

 

 

 

112

 

 

 

Acetyl Chain

61

 

 

 

 

57

 

 

 

 

217

 

 

 

 

54

 

 

 

 

55

 

 

 

 

54

 

 

 

 

54

 

 

 

Other Activities(2)

10

 

 

 

 

17

 

 

 

 

27

 

 

 

 

8

 

 

 

 

7

 

 

 

 

6

 

 

 

 

6

 

 

 

Total

181

 

 

 

 

176

 

 

 

 

691

 

 

 

 

174

 

 

 

 

173

 

 

 

 

172

 

 

 

 

172

 

 

 

Operating EBITDA / Operating EBITDA Margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Engineered Materials

375

 

 

25.6

%

 

303

 

 

22.0

%

 

1,295

 

 

21.1

%

 

311

 

 

22.1

%

 

340

 

 

22.3

%

 

317

 

 

20.0

%

 

327

 

 

20.1

%

Acetyl Chain

338

 

 

28.1

%

 

353

 

 

28.0

%

 

1,475

 

 

30.2

%

 

354

 

 

30.0

%

 

365

 

 

29.9

%

 

386

 

 

31.3

%

 

370

 

 

29.6

%

Other Activities(2)

(81

)

 

 

 

(73

)

 

 

 

(326

)

 

 

 

(57

)

 

 

 

(81

)

 

 

 

(87

)

 

 

 

(101

)

 

 

Total

632

 

 

23.8

%

 

583

 

 

22.3

%

 

2,444

 

 

22.3

%

 

608

 

 

23.7

%

 

624

 

 

22.9

%

 

616

 

 

22.0

%

 

596

 

 

20.9

%

___________________________

(1)

Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.

(2)

Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

 

Table 3

Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

 

 

per share

 

(In $ millions, except per share data)

Earnings (loss) from continuing operations attributable to Celanese Corporation

156

 

 

1.42

 

121

 

 

1.10

 

1,969

 

 

18.00

 

704

 

 

6.43

 

952

 

 

8.70

 

219

 

 

2.00

 

94

 

 

0.86

Income tax provision (benefit)

29

 

 

 

 

33

 

 

 

 

(790

)

 

 

 

(575

)

 

 

 

(236

)

 

 

 

(4

)

 

 

 

25

 

 

 

Earnings (loss) from continuing operations before tax

185

 

 

 

 

154

 

 

 

 

1,179

 

 

 

 

129

 

 

 

 

716

 

 

 

 

215

 

 

 

 

119

 

 

 

Certain Items attributable to Celanese Corporation (Table 8)

102

 

 

 

 

97

 

 

 

 

(114

)

 

 

 

139

 

 

 

 

(438

)

 

 

 

54

 

 

 

 

131

 

 

 

Refinancing and related expenses

 

 

 

 

 

 

7

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

Adjusted earnings (loss) from continuing operations before tax

287

 

 

 

 

251

 

 

 

 

1,072

 

 

 

 

268

 

 

 

 

285

 

 

 

 

269

 

 

 

 

250

 

 

 

Income tax (provision) benefit on adjusted earnings(1)

(26

)

 

 

 

(23

)

 

 

 

(96

)

 

 

 

(23

)

 

 

 

(11

)

 

 

 

(32

)

 

 

 

(30

)

 

 

Adjusted earnings (loss) from continuing operations(2)

261

 

 

2.38

 

228

 

 

2.08

 

976

 

 

8.92

 

245

 

 

2.24

 

274

 

 

2.50

 

237

 

 

2.17

 

220

 

 

2.01

 

Diluted shares (in millions)(3)

Weighted average shares outstanding

109.3

 

 

 

 

109.1

 

 

 

 

108.8

 

 

 

 

109.0

 

 

 

 

108.9

 

 

 

 

108.9

 

 

 

 

108.6

 

 

 

Incremental shares attributable to equity awards

0.2

 

 

 

 

0.4

 

 

 

 

0.6

 

 

 

 

0.5

 

 

 

 

0.5

 

 

 

 

0.4

 

 

 

 

0.6

 

 

 

Total diluted shares

109.5

 

 

 

 

109.5

 

 

 

 

109.4

 

 

 

 

109.5

 

 

 

 

109.4

 

 

 

 

109.3

 

 

 

 

109.2

 

 

 

______________________________

(1)

Calculated using adjusted effective tax rates (Table 3a) as follows:

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

 

Adjusted effective tax rate

9

 

 

 

9

 

 

 

9

 

 

 

9

 

 

 

4

 

 

 

12

 

 

 

12

 

 

(2)

Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.

 

 

Actual Plan

Asset Returns

 

Expected

Plan Asset

Returns

 

 

(In percentages)

2023

 

8.1

 

5.2

(3)

Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.

 

Table 3a

Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited

 

Estimated

 

Actual

 

 

2024

 

2023

 

 

(In percentages)

 

US GAAP annual effective tax rate

20

 

 

(67

)

 

Discrete quarterly recognition of GAAP items(1)

(1

)

 

2

 

 

Tax impact of other charges and adjustments(2)

(1

)

 

(3

)

 

Changes in valuation allowances, excluding impact of other charges and adjustments(3)

(6

)

 

13

 

 

Other, includes effect of discrete current year transactions(4)

(3

)

 

64

 

(5)

Adjusted tax rate

9

 

 

9

 

 

_____________________________

Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.

(1)

Such as changes in tax laws (including US tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.

(2)

Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.

(3)

Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.

(4)

Includes tax impacts related to full-year actual tax opportunities and related costs, as well as current year realization of U.S. GAAP benefits deferred in prior years.

(5)

Includes the reversal of certain U.S. GAAP deferred tax benefits related to non-recurring internal restructuring transactions related to the M&M acquisition, to centralize ownership of intellectual property with the business and to facilitate future deployment of cash to service acquisition indebtedness. Certain benefits of the internal restructuring will be realized in future periods for adjusted earnings purposes.

 

Table 4

Net Sales by Segment - Unaudited

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions)

Engineered Materials

1,467

 

 

1,378

 

 

6,149

 

 

1,406

 

 

1,528

 

 

1,585

 

 

1,630

 

Acetyl Chain

1,202

 

 

1,261

 

 

4,884

 

 

1,181

 

 

1,220

 

 

1,233

 

 

1,250

 

Intersegment eliminations(1)

(18

)

 

(28

)

 

(93

)

 

(18

)

 

(25

)

 

(23

)

 

(27

)

Net sales

2,651

 

 

2,611

 

 

10,940

 

 

2,569

 

 

2,723

 

 

2,795

 

 

2,853

 

___________________________

(1)

Includes intersegment sales primarily related to the Acetyl Chain.

 

Table 4a

Factors Affecting Segment Net Sales Sequentially - Unaudited

 

Three Months Ended June 30, 2024 Compared to Three Months Ended March 31, 2024

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

7

 

 

 

 

(1

)

 

6

 

 

Acetyl Chain

(1

)

 

(4

)

 

 

 

(5

)

 

 

 

 

 

 

 

 

 

 

Total Company

4

 

 

(2

)

 

 

 

2

 

 

Three Months March 31, 2024 Compared to Three Months Ended December 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(1

)

 

(1

)

 

 

(2

)

 

Acetyl Chain

5

 

 

1

 

 

1

 

7

 

 

 

 

 

 

 

 

 

 

 

Total Company

2

 

 

 

 

 

2

 

 

Three Months Ended December 31, 2023 Compared to Three Months Ended September 30, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(5

)

 

(3

)

 

 

(8

)

(1)

Acetyl Chain

 

 

(3

)

 

 

(3

)

 

 

 

 

 

 

 

 

 

 

Total Company

(3

)

 

(3

)

 

 

(6

)

 

Three Months Ended September 30, 2023 Compared to Three Months Ended June 30, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(1

)

 

(3

)

 

 

 

(4

)

 

Acetyl Chain

3

 

 

(3

)

 

(1

)

 

(1

)

 

 

 

 

 

 

 

 

 

 

Total Company

1

 

 

(3

)

 

(1

)

 

(3

)

 

________________________

(1)

Includes the effect of the formation of the Nutrinova joint venture.

Three Months Ended June 30, 2023 Compared to Three Months Ended March 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

2

 

(5

)

 

 

(3

)

 

Acetyl Chain

2

 

(3

)

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

Total Company

2

 

(4

)

 

 

(2

)

 

Three Months Ended March 31, 2023 Compared to Three Months Ended December 31, 2022

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

34

 

(4

)

 

2

 

32

 

Acetyl Chain

10

 

(2

)

 

2

 

10

 

 

 

 

 

 

 

 

 

 

Total Company

19

 

(4

)

 

2

 

17

 

 

Table 4b

Factors Affecting Segment Net Sales Year Over Year - Unaudited

 

Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(2

)

 

(4

)

 

(1

)

 

(7

)

 

Acetyl Chain

4

 

 

(6

)

 

(1

)

 

(3

)

 

 

 

 

 

 

 

 

 

 

Total Company

1

 

 

(5

)

 

(1

)

 

(5

)

 

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

(12

)

 

(2

)

 

(1

)

 

(15

)

 

Acetyl Chain

11

 

 

(10

)

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

Total Company

(2

)

 

(5

)

 

(1

)

 

(8

)

 

Three Months Ended December 31, 2023 Compared to Three Months Ended December 31, 2022

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

21

 

(8

)

 

1

 

14

 

Acetyl Chain

14

 

(11

)

 

1

 

4

 

 

 

 

 

 

 

 

 

 

Total Company

18

 

(10

)

 

1

 

9

 

Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022

 

Volume

��

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

75

 

(12

)

 

1

 

64

 

 

Acetyl Chain

4

 

(18

)

 

1

 

(13

)

 

 

 

 

 

 

 

 

 

 

Total Company

33

 

(16

)

 

1

 

18

 

 

Three Months Ended June 30, 2023 Compared to Three Months Ended June 30, 2022

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

75

 

 

(8

)

 

 

67

 

 

Acetyl Chain

(2

)

 

(19

)

 

 

(21

)

 

 

 

 

 

 

 

 

 

 

Total Company

27

 

 

(15

)

 

 

12

 

 

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

80

 

 

2

 

 

(3

)

 

79

 

 

Acetyl Chain

(9

)

 

(13

)

 

(2

)

 

(24

)

 

 

 

 

 

 

 

 

 

 

Total Company

23

 

 

(8

)

 

(3

)

 

12

 

 

 

Table 4c

Factors Affecting Segment Net Sales Year Over Year - Unaudited

 

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

 

Volume

 

Price

 

Currency

 

Total

 

 

(In percentages)

 

Engineered Materials

54

 

(1

)

 

 

53

 

 

Acetyl Chain

2

 

(17

)

 

 

(15

)

 

 

 

 

 

 

 

 

 

 

Total Company

23

 

(10

)

 

 

13

 

 

 

Table 5

Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions, except percentages)

Net cash provided by (used in) investing activities

(91

)

 

(151

)

 

(134

)

 

(168

)

 

375

 

 

(163

)

 

(178

)

Net cash provided by (used in) financing activities

(489

)

 

(259

)

 

(1,456

)

 

(240

)

 

(700

)

 

(447

)

 

(69

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities

292

 

 

101

 

 

1,899

 

 

830

 

 

403

 

 

762

 

 

(96

)

Capital expenditures on property, plant and equipment

(105

)

 

(137

)

 

(568

)

 

(128

)

 

(131

)

 

(145

)

 

(164

)

Contributions from/(Distributions) to NCI

(14

)

 

(4

)

 

(11

)

 

 

 

(4

)

 

(6

)

 

(1

)

Free cash flow(1)

173

 

 

(40

)

 

1,320

 

 

702

 

 

268

 

 

611

 

 

(261

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

2,651

 

 

2,611

 

 

10,940

 

 

2,569

 

 

2,723

 

 

2,795

 

 

2,853

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Free cash flow as % of Net sales

6.5

%

 

(1.5

)%

 

12.1

%

 

27.3

%

 

9.8

%

 

21.9

%

 

(9.1

)%

______________________________

(1)

Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures.

 

Table 6

Cash Dividends Received - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions)

Dividends from equity method investments

69

 

27

 

157

 

85

 

7

 

25

 

40

Dividends from equity investments without readily determinable fair values

31

 

34

 

126

 

31

 

30

 

31

 

34

Total

100

 

61

 

283

 

116

 

37

 

56

 

74

 

Table 7

Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

(In $ millions)

Short-term borrowings and current installments of long-term debt - third party and affiliates

1,977

 

 

2,439

 

 

1,383

 

 

1,383

 

 

1,408

 

 

1,507

 

 

1,386

 

Long-term debt, net of unamortized deferred financing costs

11,058

 

 

11,018

 

 

12,301

 

 

12,301

 

 

12,291

 

 

12,889

 

 

13,396

 

Total debt

13,035

 

 

13,457

 

 

13,684

 

 

13,684

 

 

13,699

 

 

14,396

 

 

14,782

 

Cash and cash equivalents

(1,185

)

 

(1,483

)

 

(1,805

)

 

(1,805

)

 

(1,357

)

 

(1,296

)

 

(1,167

)

Net debt

11,850

 

 

11,974

 

 

11,879

 

 

11,879

 

 

12,342

 

 

13,100

 

 

13,615

 

 

Table 8

Certain Items - Unaudited

The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:

 

Q2 '24

 

Q1 '24

 

2023

 

Q4 '23

 

Q3 '23

 

Q2 '23

 

Q1 '23

 

Income Statement Classification

 

(In $ millions)

 

 

Exit and shutdown costs

69

 

68

 

 

89

 

 

33

 

 

9

 

 

21

 

26

 

Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Non-operating pension and other postretirement employee benefit (expense) income

Asset impairments

3

 

 

 

 

15

 

 

6

 

 

9

 

 

 

 

 

 

Cost of sales / Other (charges) gains, net

Impact from plant incidents and natural disasters(1)

 

 

7

 

 

6

 

 

 

 

 

 

 

 

6

 

 

Cost of sales

Mergers, acquisitions and dispositions

26

 

 

25

 

 

195

 

 

27

 

 

46

 

 

23

 

 

99

 

 

Cost of sales / SG&A

Actuarial (gain) loss on pension and postretirement plans

 

 

 

 

69

 

 

69

 

 

 

 

 

 

 

 

Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income

Legal settlements and commercial disputes

3

 

 

(8

)

 

12

 

 

4

 

 

2

 

 

6

 

 

 

 

Cost of sales / SG&A / Other (charges) gains, net

(Gain) loss on disposition of businesses and assets

1

 

 

 

 

(510

)

 

(3

)

 

(508

)

 

1

 

 

 

 

Gain (loss) on disposition of businesses and assets, net

Other

 

 

5

 

 

10

 

 

3

 

 

4

 

 

3

 

 

 

 

Cost of sales / SG&A

Certain Items attributable to Celanese Corporation

102

 

 

97

 

 

(114

)

 

139

 

 

(438

)

 

54

 

 

131

 

 

 

___________________________

(1)

Primarily associated with Winter Storms Heather and Elliott in 2024 and 2023, respectively.

 

Table 9

Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited

 

 

 

 

 

2023

 

 

 

 

 

(In $ millions, except percentages)

Net earnings (loss) attributable to Celanese Corporation

 

 

 

 

1,960

 

 

 

 

 

 

 

Adjusted EBIT (Table 1)

 

 

 

 

1,753

 

Adjusted effective tax rate (Table 3a)

 

 

 

 

9

%

Adjusted EBIT tax effected

 

 

 

 

1,595

 

 

 

 

 

 

 

 

2023

 

2022

 

Average

 

(In $ millions, except percentages)

Short-term borrowings and current installments of long-term debt - third parties and affiliates

1,383

 

1,306

 

1,345

 

Long-term debt, net of unamortized deferred financing costs

12,301

 

13,373

 

12,837

 

Celanese Corporation shareholders' equity

7,091

 

5,637

 

6,364

 

Invested capital

 

 

 

 

20,546

 

 

 

 

 

 

 

Return on invested capital (adjusted)

 

 

 

 

7.8

%

 

 

 

 

 

 

Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital

 

 

 

 

9.5

%

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.